Understanding Promethazine's BNF Safety Guidelines
BNF Safety Classification and Risk Assessment
According to British National Formulary guidelines, promethazine (Phenergan) is classified as a sedating antihistamine with a well-established safety profile when used appropriately. The BNF categorises promethazine under first-generation antihistamines, noting its dual therapeutic effects and associated precautions. EverydayMeds stocks both Phenergan 25mg tablets and Phenergan Elixir 5mg/5ml oral solution to accommodate different patient needs and preferences.
Common and Serious Side Effects Profile
The BNF documents promethazine's side effects by frequency. Common effects (occurring in more than 1 in 100 people) include drowsiness, dry mouth, blurred vision, and dizziness. These anticholinergic effects are dose-dependent and typically mild. Uncommon effects include headache, nightmares, and gastrointestinal disturbances. Rare but serious effects include blood disorders, liver dysfunction, and severe allergic reactions. The sedating properties, while therapeutic for sleep issues, can impair driving ability and cognitive function for up to 24 hours.
Special Population Safety Considerations
Elderly patients require particular attention when using promethazine, as the BNF highlights increased sensitivity to anticholinergic effects. This population faces higher risks of confusion, falls, and urinary retention. Lower starting doses are recommended, typically beginning with 10mg rather than 25mg. Pregnant women should note that promethazine is generally considered safe in pregnancy (Pregnancy Category C), though first-trimester use requires careful consideration. Breastfeeding mothers should be aware that small amounts pass into breast milk, potentially causing sedation in infants.
Contraindications and Absolute Safety Restrictions
The BNF lists several absolute contraindications for promethazine. These include known hypersensitivity to phenothiazines, severe liver disease, and concurrent use with MAO inhibitors. Patients with narrow-angle glaucoma, severe asthma, or bladder neck obstruction should avoid promethazine due to its anticholinergic properties. Children under 2 years should not receive promethazine due to increased risk of respiratory depression. The medication is also contraindicated in comatose patients or those with severe CNS depression.
Drug Interactions and Safety Monitoring
Promethazine interacts with numerous medications, requiring careful safety assessment. Concurrent use with other CNS depressants (alcohol, benzodiazepines, opioids) significantly increases sedation and respiratory depression risks. The BNF warns against combining promethazine with anticholinergic drugs, as this amplifies dry mouth, constipation, and urinary retention. MAO inhibitors can cause dangerous hypertensive reactions. Regular monitoring is advised for patients on long-term therapy, including liver function tests and blood counts. EverydayMeds recommends consulting healthcare providers before starting promethazine, particularly when taking other medications or having underlying health conditions.
